HSS Journal

, 5:149

Recent Advances Toward the Clinical Application of PTH (1-34) in Fracture Healing

  • Cara A. Cipriano
  • Paul S. Issack
  • Lisa Shindle
  • Clément M. L. Werner
  • David L. Helfet
  • Joseph M. Lane
 

DOI: 10.1007/s11420-009-9109-8

Cite this article as:
Cipriano, C.A., Issack, P.S., Shindle, L. et al. HSS Jrnl (2009) 5: 149. doi:10.1007/s11420-009-9109-8

Abstract

PTH 1-34, an active form of parathyroid hormone, has been shown to enhance osteoblastic bone formation when administered as a daily subcutaneous injection. The effect of the intermittent administration of PTH (1-34) is an uncoupling of bone turnover with an increase in bone mass and density and decrease in risk of vertebral and nonvertebral fractures. While PTH (1-34) has been used clinically to increase bone mass and reduce fracture risk in postmenopausal women with osteoporosis, there is increasing evidence that PTH (1-34) may promote fracture healing. Animal studies have demonstrated accelerated callus formation with enhanced remodeling and biomechanical properties of the healing fracture. Given these effects, PTH (1-34) will likely be used clinically to enhance fracture union in poor healing situations such as osteoporosis and recalcitrant nonunions.

Copyright information

© Hospital for Special Surgery 2009

Authors and Affiliations

  • Cara A. Cipriano
    • 3
  • Paul S. Issack
    • 1
    • 2
  • Lisa Shindle
    • 4
  • Clément M. L. Werner
    • 1
  • David L. Helfet
    • 1
    • 5
  • Joseph M. Lane
    • 4
  1. 1.Orthopaedic Trauma ServiceHospital for Special SurgeryNew YorkUSA
  2. 2.Orthopaedic Trauma and Adult Reconstructive SurgeryHospital for Special SurgeryNew YorkUSA
  3. 3.University of Pennsylvania School of MedicinePhiladelphiaUSA
  4. 4.Metabolic Bone Disease ServiceHospital for Special SurgeryNew YorkUSA
  5. 5.Weill-Cornell Medical CenterNew YorkUSA

Personalised recommendations